Positive data for Galapagos fibrosis drug

A Phase 2a study of a drug developed by Galapagos NV for patients with idiopathic pulmonary fibrosis has halted the progression of the disease in a randomised, placebo-controlled study. Galapagos said it is making plans for a late-stage trial.

Full text available to subscribers only. Click here for information on subscribing to MedNous.